PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups-Reference-Cited by-同舟云学术

PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups

Published:2012-02 Issue:1 Volume:14 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Cizkova Magdalena,Susini Aurélie,Vacher Sophie,Cizeron-Clairac Géraldine,Andrieu Catherine,Driouch Keltouma,Fourme Emmanuelle,Lidereau Rosette,Bièche Ivan

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr3113.pdf

Reference35 articles.

1. Zhao L, Vogt PK: Class I PI3K in oncogenic cellular transformation. Oncogene. 2008, 27: 5486-5496. 10.1038/onc.2008.244.

2. Dillon RL, White DE, Muller WJ: The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene. 2007, 26: 1338-1345. 10.1038/sj.onc.1210202.

3. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005, 7: 561-573. 10.1016/j.ccr.2005.05.014.

4. Karakas B, Bachman KE, Park BH: Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006, 94: 455-459. 10.1038/sj.bjc.6602970.

5. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM: The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA. 2005, 102: 18443-18448. 10.1073/pnas.0508988102.

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PIK3CA mutation analysis in circulating tumor cells of patients with hormone receptor positive metastatic breast cancer;Biochemistry and Biophysics Reports;2024-09

2. PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer;Cancer Medicine;2024-09

3. Wise and skillful utilization of contemporary endocrine therapies for the treatment of ER+/HER2– advanced breast cancer;Oncology in Clinical Practice;2024-08-21

4. A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis;Breast Disease;2024-06-28

5. Survival analysis of patients with early breast cancer associated with PIK3CA mutation;2024-06-20